Natera, Inc.
A clinical genetics company that reads traces of DNA floating in the blood to detect cancer, screen pregnancies, and monitor transplanted organs — its best-known tests include Signatera for cancer recurrence, Panorama for prenatal screening, and Prospera for transplant rejection. It began in 2004 as Gene Security Network, born from a founder's personal loss when a relative's baby died days after birth with an undetected condition. The company later renamed itself Natera, a word meant to echo "birth," "nature," and "earth."
Granted 1.70M · Bought 219.8K · Sold 888.8K
Granted 13.8K · Sold 646.4K
Granted 29.7K · Bought 153.0K · Sold 240.5K
Granted 238.5K · Sold 386.7K
Granted 136.6K · Sold 75.7K
Granted 427.7K · Sold 284.5K
Granted 183.3K · Sold 77.7K
Granted 1.31M · Sold 1.28M
Granted 202.9K · Sold 231.4K
Granted 457.3K · Sold 495.6K
Granted 67.3K · Sold 50.0K
Granted 27.1K · Sold 24.3K
Granted 51.5K · Sold 49.3K
Granted 8.0K
Granted 158.0K · Sold 203.4K
Granted 5.5K
Granted 28.6K · Sold 28.7K
Granted 2.2K
Granted 1.9K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Rabinowitz MatthewEXECUTIVE CHAIRMAN, Director · 143 transactions | — | 2.29M | 1.70M | 219.8K | 888.8K |
| Healy JamesDirector · 18 transactions | +0.9% | 1.60Mas of Apr 2025 | 13.8K | — | 646.4K |
| Botha RoelofDirector · 51 transactions | -5.1% | 1.08M | 29.7K | 153.0K | 240.5K |
| Sheena JonathanDirector, CO-FOUNDER · 439 transactions | — | 288.4K | 238.5K | — | 386.7K |
| Schueren Robert AlanCHIEF OPERATING OFFICER · 60 transactions | — | 241.6Kas of Jan 2023 | 136.6K | — | 75.7K |
| Rabinowitz DanielSEC. AND CHIEF LEGAL OFFICER · 177 transactions | +318.4% | 206.5K | 427.7K | — | 284.5K |
| Fesko JohnPRESIDENT, CHIEF BUS. OFFICER · 62 transactions | — | 185.8K | 183.3K | — | 77.7K |
| Chapman Steven LeonardCEO AND PRESIDENT, Director · 322 transactions | +53.3% | 139.7K | 1.31M | — | 1.28M |
| Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS · 134 transactions | — | 137.6K | 202.9K | — | 231.4K |
| Brophy Michael BurkesCHIEF FINANCIAL OFFICER · 251 transactions | -41.2% | 57.5K | 457.3K | — | 495.6K |
| Baynes Roy D.Director · 42 transactions | +603.2% | 20.1K | 67.3K | — | 50.0K |
| Cozzens Todd CDirector · 7 transactions | -62% | 15.8Kas of May 2022 | 27.1K | — | 24.3K |
| Marcus Gail BoxerDirector · 61 transactions | +37.5% | 7.9K | 51.5K | — | 49.3K |
| Bertagnolli MonicaDirector · 10 transactions | — | 6.9K | 8.0K | — | — |
| Rosenman HermDirector · 39 transactions | -88.6% | 5.8K | 158.0K | — | 203.4K |
| Williams Brinkley RuthDirector · 6 transactions | — | 5.5K | 5.5K | — | — |
| Chapman Rowan EDirector · 31 transactions | -53.7% | 4.8K | 28.6K | — | 28.7K |
| Rubin Eric HDirector · 3 transactions | — | 2.2K | 2.2K | — | — |
| Lynch Thomas J. Jr.Director · 1 transaction | — | 1.9K | 1.9K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -4.59M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.